Introduction
Theiler's murine encephalomyelitis virus (TMEV) is a common enteric pathogen in mice and belongs to the Cardiovirus genus within the Picornavirus family (Theiler, 1934) . TMEV infection leads to a chronic viral persistence in the central nervous system (CNS) and an immunemediated demyelinating disease similar to human multiple sclerosis in susceptible mouse strains (Kim et al., 2000) . TMEV infects neurons, various glial cells including astrocytes and microglia, as well as professional antigen-presenting cells (APCs) including macrophages and dendritic cells (DCs) (Sethi and Lipton, 1983; Palma et al., 2003; Hou et al., 2007; Jin et al., 2007) . TMEV infection induces various chemokines and cytokines, including type I interferon (IFN-I), primarily via TLR3 and MDA5-dependent pathways (Delhaye et al., 2006; So et al., 2006) . Interferons (IFNs), cytokines interfering with virus replication at the early stage of infection (Isaacs and Lindenmann, 1957) , are classified as type I, type II and type III IFNs depending on their function and structures (Pestka et al., 2004; Takaoka and Yanai, 2006) . IFN-α and -β share a heterodimeric receptor composed of IFNAR1 and IFNAR2 subunits, which are both required for signal transduction (Theofilopoulos et al., 2005) .
In addition to the direct anti-viral function, IFN-I is known to play critical roles in many aspects of immune responses. For example, IFN-I is required for the activation and survival of T cells (Curtsinger et al., 2005; Kolumam et al., 2005; Havenar-Daughton et al., 2006) . In addition, IFN-I can directly activate NK cells to enhance their cytotoxic activity (Biron et al., 1999; Lee et al., 2000; Nguyen et al., 2002) . Moreover, IFN-I is essential for facilitating the efficient APC function for T cell activation. IFN-I enhances the expression of MHC class I and class II molecules (Satoh et al., 1995; Ireland et al., 2008) , as well as costimulatory molecules, such as CD80, CD86 and CD40 on APCs (Gallucci et al., 1999; Santini et al., 2000; Montoya et al., 2002) . However, the level of IFN-I appears to play a regulatory role in either enhancement or inhibition of immune responses, i.e. a low dose enhances but a high concentration inhibits (Biron, 2001) . It is interesting to note that IFN-I induces Th2 cytokines such as IL-10 and IL-4 and down-regulates Th1-associated genes such as IL-12 receptor β2 (Rudick et al., 1996; Wandinger et al., 2001) . Furthermore, IFN-I is also involved in the reduction of blood-brain-barrier (BBB) permeability (Stone et al., 1995) . In fact, IFN-I is a frequently used therapeutic agent for the treatment of MS, despite its potential immune enhancing function (Goodin, 2001; Vermersch et al., 2002) . Although the mechanisms are not known, it is likely that the Journal of Neuroimmunology 226 (2010) 27-37
